NRX Pharmaceuticals, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q2 2020 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
NRX Pharmaceuticals, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q2 2020 to Q3 2024.
  • NRX Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $104K, a 70.4% decline year-over-year.
  • NRX Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $2.32M, a 70.2% decline from 2021.
  • NRX Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $7.79M, a 966% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $104K -$247K -70.4% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 $97K -$447K -82.2% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 $242K -$453K -65.2% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q3 2023 $1.05M $351K -$190K -35.1% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 $1.24M $544K -$443K -44.9% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 $1.68M $695K -$639K -47.9% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 $2.32M -$541K -$2.11M -134% Oct 1, 2022 Dec 31, 2022 10-Q 2023-08-14
Q3 2022 $4.43M $541K -$1.02M -65.3% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 $5.45M $987K -$3.3M -77% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 $8.75M $1.33M +$962K +259% Jan 1, 2022 Mar 31, 2022 10-Q 2022-05-16
Q4 2021 $7.79M $1.57M Oct 1, 2021 Dec 31, 2021 10-K 2023-03-31
Q3 2021 $1.56M +$1.37M +718% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 $4.28M +$4.19M +4482% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-15
Q1 2021 $372K Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q3 2020 $191K Jul 1, 2020 Sep 30, 2020 10-Q/A 2022-08-12
Q2 2020 $93.5K Apr 1, 2020 Jun 30, 2020 10-Q/A 2022-08-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.